Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in NK cells from ME/CFS patients, Cabanas et al, 2019

Simone said:
Sadly, Jarred Younger’s trial has been suspended, though I’m not sure why. It was suspended without having started. No participants had been deemed eligible or had started on the protocol.
https://clinicaltrials.gov/ct2/show...e+syndrome&cntry=US&state=US:AL&draw=2&rank=1
Click to expand...
Younger did do two trials in Fibromylagia at Stanford using LDN
https://clinicaltrials.gov/ct2/resu...exone&cntry=&state=&city=&dist=&Search=Search

and as I posted on the another thread earlier, there have been 40 clinical trials registered using Naltrexone
https://clinicaltrials.gov/ct2/resu...prcd_e=&sfpd_s=&sfpd_e=&lupd_s=&lupd_e=&sort=
 
wigglethemouse said:
Agree. Also, I'd imagine that it is hard to do a blinded trial using LDN. Many people get disturbed sleep when starting, and have to ramp slowly.

EDIT: In FM he did immune monitoring at baseline and at end that may interest some folks
https://clinicaltrials.gov/ct2/show/results/NCT02107014?term=low+dose+naltrexone&draw=2&rank=3
Click to expand...

Most drugs produce some sort of side effects. It usually doesn't prevent from using them in blinded trials, otherwise we would have no approved drugs for anything. But yeah, I'd be really curious to know why he suspended the trial.

I sometimes wonder if it's again the curse on ME/CFS at play when scientists can't seem to even get phase 1 drug trials for ME/CFS finished (apart from the rituximab one). Oh and it seems his LDN trial wasn't even placebo controlled.
 
Last edited:
JES said:
Oh and it seems his LDN trial wasn't even placebo controlled.
Click to expand...
The larger clinical trial he did had a sugar pill placebo arm
https://clinicaltrials.gov/ct2/show...se+naltrexone&cond=Fibromyalgia&draw=2&rank=3

Here is the paper he wrote in that Fibromyalgia LDN study
https://www.ncbi.nlm.nih.gov/pubmed/23359310
RESULTS:
When contrasting the condition end points, we observed a significantly greater reduction of baseline pain in those taking low-dose naltrexone than in those taking placebo (28.8% reduction versus 18.0% reduction; P = 0.016). Low-dose naltrexone was also associated with improved general satisfaction with life (P = 0.045) and with improved mood (P = 0.039), but not improved fatigue or sleep.

Thirty-two percent of participants met the criteria for response (defined as a significant reduction in pain plus a significant reduction in either fatigue or sleep problems) during low-dose naltrexone therapy, as contrasted with an 11% response rate during placebo therapy (P = 0.05).

Low-dose naltrexone was rated equally tolerable as placebo, and no serious side effects were reported.
Click to expand...
 
MEA Summary Review: Low Dose Naltrexone (LDN) in ME/CFS | 14 November 2019

https://www.meassociation.org.uk/20...se-naltrexone-ldn-in-me-cfs-14-november-2019/

Charlotte Stephens, Research Correspondent, ME Association.

A recent publication by researchers from Griffith University in Australia examined the possible therapeutic mechanisms of a drug called ‘Naltrexone’ in ME/CFS patients.

In this summary review, we explain what Naltrexone is, how it works, what it’s used for and why it might be useful as a treatment for ME/CFS, as well as discussing the findings from this latest study...
 
I’ve noticed it seems to work best for those who start really low and keep to a really low dose rather than go in at 4.5mg or work up to that. Starting low at 0.5ml and working up at using that dose every two weeks seems to be successful for most.
 
You must log in or register to reply here.
Back
Top Bottom